vedolizumab vs Zotemtegrast

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: α4β7 integrin · full Ulcerative Colitis pipeline

vedolizumab · Entyvio

Marketed by Takeda Pharmaceutical Company

Approved in Ulcerative Colitismonoclonal antibody (humanized IgG1)
Reliable signal

NCT00783718 · Phase 3 · completed

Randomized, triple-blind, placebo-controlled, adequately powered (n=895) phase 3 design with hard clinical endpoints (Mayo score-based clinical response/remission), and both primary endpoint comparisons reached statistical significance in the favorable direction (Induction: p<0.0001, RD 21.7%; Maintenance: p<0.0001 for both dose arms vs placebo) — meeting the 'strong' test.

Next expected readout: May 2027 · NCT06581328 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Clinical Remission (Week 52): Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg) (met)

Result source: NCT02497469

Zotemtegrast

Developed by Eli Lilly

Phase 2 in Ulcerative ColitisSmall molecule (oral α4β7 integrin inhibitor)
Weak signal

NCT05291689 · Phase 2 · completed

This was a single-group, open-label study with 39 participants overall and no placebo or active comparator. The primary clinical/histopathology endpoint was reported as a mean change, but without a comparator there was no formal between-group comparison to establish efficacy.

Next expected readout: May 2027 · NCT07186101 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% (missed)

Result source: NCT05611671

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointvedolizumabZotemtegrast
Clinical remission (induction)18.3% vs 12.2%+6.1 vs placebo300 mg · wk 10 · n 164NCT02039505
1 other result
  • 16.9% vs 5.4% wk 6 · n 225 · Phase 3 · secondary NCT00783718
31.9% vs 24.3%+7.6 vs placebo200 mg BID · wk 12 · n 69NCT05611671
2 other results
  • 23.9% vs 24.3% 100 mg BID · wk 12 · n 71 · Phase 2 · primary NCT05611671
  • 17.1% vs 24.3% 100 mg QD-M · wk 12 · n 70 · Phase 2 · primary NCT05611671
Clinical remission (maintenance)46.2% vs 14.3%+31.9 vs placebo108 mg SC · wk 52 · n 106NCT02611830
4 other results
  • 41.8% vs 15.9% Q8W · wk 52 · n 122 · Phase 3 · primary NCT00783718
  • 44.8% vs 15.9% Q4W · wk 52 · n 125 · Phase 3 · primary NCT00783718
  • 56.1% vs 31% 300 mg · wk 60 · n 41 · Phase 3 · primary NCT02039505
  • 31.3% vs 22.5% 300 mg IV · wk 52 · n 383 · Phase 3 · primary NCT02497469
—Not reported
Clinical response (induction)39.6% vs 32.9%+6.7 vs placebo300 mg · wk 10 · n 164NCT02039505
1 other result
  • 47.1% vs 25.5% wk 6 · n 225 · Phase 3 · primary NCT00783718
62.3% vs 54.3%+8 vs placebo200 mg BID · wk 12 · n 69NCT05611671
2 other results
  • 53.5% vs 54.3% 100 mg BID · wk 12 · n 71 · Phase 2 · secondary NCT05611671
  • 57.1% vs 54.3% 100 mg QD-M · wk 12 · n 70 · Phase 2 · secondary NCT05611671
Endoscopic improvement (induction)36.6% vs 30.5%+6.1 vs placebo300 mg · wk 10 · n 164NCT02039505
1 other result
  • 40.9% vs 24.8% wk 6 · n 225 · Phase 3 · secondary NCT00783718
—Not reported
Corticosteroid-free remission (maintenance)28.9% vs 8.3%+20.6 vs placebo108 mg SC · wk 52 · n 45NCT02611830
4 other results
  • 31.4% vs 13.9% Q8W · wk 52 · n 70 · Phase 3 · secondary NCT00783718
  • 45.2% vs 13.9% Q4W · wk 52 · n 73 · Phase 3 · secondary NCT00783718
  • 46.2% vs 20% 300 mg · wk 60 · n 13 · Phase 3 · secondary NCT02039505
  • 12.6% vs 21.8% 300 mg IV · wk 52 · n 111 · Phase 3 · secondary NCT02497469
—Not reported

Clinical remission (induction)

vedolizumab
18.3% vs 12.2%+6.1 vs placebo300 mg · wk 10 · n 164NCT02039505
1 other result
  • 16.9% vs 5.4% wk 6 · n 225 · Phase 3 · secondary NCT00783718
Zotemtegrast
31.9% vs 24.3%+7.6 vs placebo200 mg BID · wk 12 · n 69NCT05611671
2 other results
  • 23.9% vs 24.3% 100 mg BID · wk 12 · n 71 · Phase 2 · primary NCT05611671
  • 17.1% vs 24.3% 100 mg QD-M · wk 12 · n 70 · Phase 2 · primary NCT05611671

Clinical remission (maintenance)

vedolizumab
46.2% vs 14.3%+31.9 vs placebo108 mg SC · wk 52 · n 106NCT02611830
4 other results
  • 41.8% vs 15.9% Q8W · wk 52 · n 122 · Phase 3 · primary NCT00783718
  • 44.8% vs 15.9% Q4W · wk 52 · n 125 · Phase 3 · primary NCT00783718
  • 56.1% vs 31% 300 mg · wk 60 · n 41 · Phase 3 · primary NCT02039505
  • 31.3% vs 22.5% 300 mg IV · wk 52 · n 383 · Phase 3 · primary NCT02497469
Zotemtegrast
—Not reported

Clinical response (induction)

vedolizumab
39.6% vs 32.9%+6.7 vs placebo300 mg · wk 10 · n 164NCT02039505
1 other result
  • 47.1% vs 25.5% wk 6 · n 225 · Phase 3 · primary NCT00783718
Zotemtegrast
62.3% vs 54.3%+8 vs placebo200 mg BID · wk 12 · n 69NCT05611671
2 other results
  • 53.5% vs 54.3% 100 mg BID · wk 12 · n 71 · Phase 2 · secondary NCT05611671
  • 57.1% vs 54.3% 100 mg QD-M · wk 12 · n 70 · Phase 2 · secondary NCT05611671

Endoscopic improvement (induction)

vedolizumab
36.6% vs 30.5%+6.1 vs placebo300 mg · wk 10 · n 164NCT02039505
1 other result
  • 40.9% vs 24.8% wk 6 · n 225 · Phase 3 · secondary NCT00783718
Zotemtegrast
—Not reported

Corticosteroid-free remission (maintenance)

vedolizumab
28.9% vs 8.3%+20.6 vs placebo108 mg SC · wk 52 · n 45NCT02611830
4 other results
  • 31.4% vs 13.9% Q8W · wk 52 · n 70 · Phase 3 · secondary NCT00783718
  • 45.2% vs 13.9% Q4W · wk 52 · n 73 · Phase 3 · secondary NCT00783718
  • 46.2% vs 20% 300 mg · wk 60 · n 13 · Phase 3 · secondary NCT02039505
  • 12.6% vs 21.8% 300 mg IV · wk 52 · n 111 · Phase 3 · secondary NCT02497469
Zotemtegrast
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. vedolizumab: 4 of 4 rows · Zotemtegrast: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricvedolizumabZotemtegrast
Dropout rate
—a
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 56 more results
—108 mg SC
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
29.9%300 mg IV
NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
23.1%300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
22.2%200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3%150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—High Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—Low Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
64.6%108 mg
NCT02620046 · Phase 3
56.6%108 mg
NCT02620046 · Phase 3
—Q2W
NCT02620046 · Phase 3
—QW
NCT02620046 · Phase 3
—Dose escalation from Q2W to QW
NCT02620046 · Phase 3
—Q2W
NCT02620046 · Phase 3
—QW
NCT02620046 · Phase 3
—Dose escalation from Q2W to QW
NCT02620046 · Phase 3
5.5%300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
21.7%300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg
NCT00790933 · Phase 3 · monotherapy
27.1%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
25.5%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
—RTP: VDZ Dose Optimization: Regime
NCT03029143 · Phase 4 · registry result, not featured evidence
—RTP: VDZ Dose Optimization: Regime
NCT03029143 · Phase 4 · registry result, not featured evidence
9.1%300 mg
NCT02559713 · Phase 4 · registry result, not featured evidence
70%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
71.4%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
71.4%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
55.6%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
75%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
40%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
28.6%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
60%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
16.7%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
41.7%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
30%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
22.2%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg to 300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
25%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
15.4%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg to 200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
18.2%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
30%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
97.1%6 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
62.2%2 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
0%10 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
0%6 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
15.4%2 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03329209 · Phase 1 · registry result, not featured evidence
1.6%750 mg
NCT01981616 · Phase 1 · registry result, not featured evidence
75%MORF-057 (Exploratory Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 4 more results
51.4%MORF-057 (Main Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
5.8%200 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
4.2%100 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
4.3%100 mg QD-M
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Discontinued due to AEs
—a
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 56 more results
—108 mg SC
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
4.2%300 mg IV
NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
2.2%300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
7.4%200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—High Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—Low Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
9.2%108 mg
NCT02620046 · Phase 3
7.6%108 mg
NCT02620046 · Phase 3
—Q2W
NCT02620046 · Phase 3
—QW
NCT02620046 · Phase 3
—Dose escalation from Q2W to QW
NCT02620046 · Phase 3
—Q2W
NCT02620046 · Phase 3
—QW
NCT02620046 · Phase 3
—Dose escalation from Q2W to QW
NCT02620046 · Phase 3
4.9%300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
15.2%300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg
NCT00790933 · Phase 3 · monotherapy
27.1%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
25.5%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
—RTP: VDZ Dose Optimization: Regime
NCT03029143 · Phase 4 · registry result, not featured evidence
—RTP: VDZ Dose Optimization: Regime
NCT03029143 · Phase 4 · registry result, not featured evidence
9.1%300 mg
NCT02559713 · Phase 4 · registry result, not featured evidence
20%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
42.9%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
42.9%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
33.3%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
30%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
40%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
16.7%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
33.3%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
10%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
11.1%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg to 300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
16.7%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
7.7%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg to 200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
18.2%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
20%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
20%6 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
0%2 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
—10 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
—6 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
—2 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03329209 · Phase 1 · registry result, not featured evidence
0%750 mg
NCT01981616 · Phase 1 · registry result, not featured evidence
75%MORF-057 (Exploratory Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 4 more results
8.6%MORF-057 (Main Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
1.4%200 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
1.4%100 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
0%100 mg QD-M
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Serious AEs
12.4%a
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 56 more results
9.4%108 mg SC
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
11%300 mg IV
NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10%300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.8%200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10.9%High Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
6.4%Low Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—108 mg
NCT02620046 · Phase 3
—108 mg
NCT02620046 · Phase 3
23%Q2W
NCT02620046 · Phase 3
29.9%QW
NCT02620046 · Phase 3
30.4%Dose escalation from Q2W to QW
NCT02620046 · Phase 3
17.8%Q2W
NCT02620046 · Phase 3
20%QW
NCT02620046 · Phase 3
36.9%Dose escalation from Q2W to QW
NCT02620046 · Phase 3
6.1%300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13%300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
9.8%300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.5%300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
36.8%300 mg
NCT00790933 · Phase 3 · monotherapy
4.2%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
5.9%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
14.3%RTP: VDZ Dose Optimization: Regime
NCT03029143 · Phase 4 · registry result, not featured evidence
3.7%RTP: VDZ Dose Optimization: Regime
NCT03029143 · Phase 4 · registry result, not featured evidence
9.1%300 mg
NCT02559713 · Phase 4 · registry result, not featured evidence
40%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
16.7%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
42.9%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
33.3%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
80%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
16.7%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
50%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
50%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
33.3%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
33.3%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
31.6%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
11.1%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
16.7%150 mg to 300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
23.5%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
50%100 mg to 200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
20%6 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
8.1%2 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
9.1%10 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
0%6 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
8.3%2 mg/kg
NCT01177228 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03329209 · Phase 1 · registry result, not featured evidence
0%750 mg
NCT01981616 · Phase 1 · registry result, not featured evidence
0%MORF-057 (Exploratory Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 4 more results
0%MORF-057 (Main Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
1.4%200 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
4.2%100 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
0%100 mg QD-M
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Most frequent reported AEs
a
headache 12.9% (placebo 8.7%)
nasopharyngitis 12.9% (placebo 7.4%)
colitis ulcerative 9.2% (placebo 13.4%)
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 46 more results
108 mg SC
colitis ulcerative 11.3% (placebo 25%)
nasopharyngitis 10.4% (placebo 19.6%)
upper respiratory tract infection 9.4% (placebo 1.8%)
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
300 mg IV
headache 7%
nasopharyngitis 7%
colitis ulcerative 6.8%
NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg
upper respiratory tract infection 15.6%
pyrexia 5.6%
anaemia 4.4%
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
200 mg
upper respiratory tract infection 29.6%
pyrexia 11.1%
clostridium difficile infection 7.4%
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
150 mg
anaemia 33.3%
gastroenteritis viral 33.3%
oral herpes 33.3%
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
High Dose
upper respiratory tract infection 17.4%
colitis ulcerative 13%
anaemia 8.7%
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Low Dose
upper respiratory tract infection 27.7%
colitis ulcerative 8.5%
influenza 8.5%
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Q2W
upper respiratory tract infection 15.9%
arthralgia 14.2%
abdominal pain 13.8%
NCT02620046 · Phase 3
QW
crohn's disease 25.6%
abdominal pain 17.1%
nasopharyngitis 13.7%
NCT02620046 · Phase 3
Dose escalation from Q2W to QW
crohn's disease 52%
nasopharyngitis 19.6%
upper respiratory tract infection 17.6%
NCT02620046 · Phase 3
Q2W
upper respiratory tract infection 17.2%
covid-19 14.7%
nasopharyngitis 14.1%
NCT02620046 · Phase 3
QW
colitis ulcerative 23.3%
nasopharyngitis 18.3%
upper respiratory tract infection 10%
NCT02620046 · Phase 3
Dose escalation from Q2W to QW
colitis ulcerative 50.8%
nasopharyngitis 23.1%
anaemia 13.8%
NCT02620046 · Phase 3
300 mg
viral upper respiratory tract infection 14% (placebo 9.8%)
headache 3.7% (placebo 2.4%)
nausea 1.2% (placebo 0%)
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg
viral upper respiratory tract infection 26.1% (placebo 9.8%)
gastroenteritis 6.5% (placebo 0%)
headache 6.5% (placebo 2.4%)
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg
viral upper respiratory tract infection 43.9% (placebo 9.8%)
dental caries 9.8% (placebo 0%)
arthralgia 7.3% (placebo 0%)
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg
viral upper respiratory tract infection 50.2% (placebo 9.8%)
influenza 9.3% (placebo 0%)
headache 8.9% (placebo 2.4%)
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg
nasopharyngitis 26.5%
arthralgia 21.5%
headache 20.2%
NCT00790933 · Phase 3 · monotherapy
300 mg
anaemia 12.5%
pyrexia 12.5%
headache 8.3%
NCT04804540 · Phase 4 · registry result, not featured evidence
300 mg
anaemia 7.8%
colitis ulcerative 6.9%
pyrexia 6.9%
NCT04804540 · Phase 4 · registry result, not featured evidence
diarrhoea 10.7%
headache 10.7%
abdominal pain upper 7.1%
NCT03029143 · Phase 4 · registry result, not featured evidence
colitis ulcerative 11.1%
anaemia 7.4%
c-reactive protein increased 7.4%
NCT03029143 · Phase 4 · registry result, not featured evidence
300 mg
crohn's disease 9.1%
gastrointestinal motility disorder 9.1%
paronychia 9.1%
NCT02559713 · Phase 4 · registry result, not featured evidence
300 mg
abdominal pain 30%
crohn's disease 30%
anaemia 20%
NCT03196427 · Phase 2 · registry result, not featured evidence
300 mg
crohn's disease 66.7%
diarrhoea 33.3%
oropharyngeal pain 33.3%
NCT03196427 · Phase 2 · registry result, not featured evidence
300 mg
arthralgia 28.6%
colitis ulcerative 28.6%
headache 28.6%
NCT03196427 · Phase 2 · registry result, not featured evidence
300 mg
colitis ulcerative 50%
abdominal pain 33.3%
diarrhoea 33.3%
NCT03196427 · Phase 2 · registry result, not featured evidence
200 mg
crohn's disease 40%
upper respiratory tract infection 40%
abdominal pain 20%
NCT03196427 · Phase 2 · registry result, not featured evidence
200 mg
pyrexia 66.7%
arthralgia 50%
colitis ulcerative 50%
NCT03196427 · Phase 2 · registry result, not featured evidence
150 mg
dehydration 50%
ear infection 50%
haemoglobin decreased 50%
NCT03196427 · Phase 2 · registry result, not featured evidence
150 mg
abdominal pain 50%
arthralgia 50%
asthma 50%
NCT03196427 · Phase 2 · registry result, not featured evidence
100 mg
anaemia 20%
asthma 20%
bronchitis 20%
NCT03196427 · Phase 2 · registry result, not featured evidence
100 mg
abdominal pain upper 33.3%
anaemia 33.3%
anaemia of chronic disease 33.3%
NCT03196427 · Phase 2 · registry result, not featured evidence
300 mg
headache 12.5%
pharyngitis 12.5%
pyrexia 12.5%
NCT03138655 · Phase 2 · registry result, not featured evidence
200 mg
abdominal pain 15.8%
anaemia 15.8%
oropharyngeal pain 15.8%
NCT03138655 · Phase 2 · registry result, not featured evidence
150 mg
ear infection 16.7%
bronchitis 11.1%
headache 11.1%
NCT03138655 · Phase 2 · registry result, not featured evidence
150 mg to 300 mg
cough 33.3%
dizziness 33.3%
headache 33.3%
NCT03138655 · Phase 2 · registry result, not featured evidence
100 mg
abdominal pain 29.4%
arthralgia 11.8%
crohn's disease 11.8%
NCT03138655 · Phase 2 · registry result, not featured evidence
100 mg to 200 mg
diarrhoea 50%
vomiting 50%
abdominal distension 25%
NCT03138655 · Phase 2 · registry result, not featured evidence
6 mg/kg
headache 20%
nasopharyngitis 20%
cough 14.3%
NCT00619489 · Phase 2 · registry result, not featured evidence
2 mg/kg
nasopharyngitis 13.5%
carpal tunnel syndrome 5.4%
headache 5.4%
NCT00619489 · Phase 2 · registry result, not featured evidence
10 mg/kg
headache 18.2% (placebo 11.1%)
balance disorder 9.1% (placebo 0%)
constipation 9.1% (placebo 11.1%)
NCT01177228 · Phase 2 · registry result, not featured evidence
6 mg/kg
headache 21.4% (placebo 11.1%)
cough 14.3% (placebo 0%)
influenza like illness 14.3% (placebo 0%)
NCT01177228 · Phase 2 · registry result, not featured evidence
2 mg/kg
colitis ulcerative 16.7% (placebo 44.4%)
headache 16.7% (placebo 11.1%)
nasopharyngitis 16.7% (placebo 11.1%)
NCT01177228 · Phase 2 · registry result, not featured evidence
300 mg
upper respiratory tract infection 25%
leukocyturia 12.5%
blood creatine phosphokinase increased 6.3%
NCT03329209 · Phase 1 · registry result, not featured evidence
750 mg
headache 18.8% (placebo 12.7%)
viral upper respiratory tract infection 12.5% (placebo 12.7%)
nausea 6.3% (placebo 0%)
NCT01981616 · Phase 1 · registry result, not featured evidence
colitis ulcerative 100%
anaemia 25%
erythema 25%
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 4 more results
colitis ulcerative 20%
anaemia 8.6%
acne 5.7%
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
200 mg BID
headache 7.1% (placebo 2.9%)
nasopharyngitis 4.3% (placebo 5.8%)
anaemia 2.9% (placebo 5.8%)
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
100 mg BID
headache 5.6% (placebo 2.9%)
nasopharyngitis 4.2% (placebo 5.8%)
anaemia 2.8% (placebo 5.8%)
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
100 mg QD-M
anaemia 4.3% (placebo 5.8%)
headache 2.9% (placebo 2.9%)
nasopharyngitis 0% (placebo 5.8%)
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2

Notes

  1. aPopulation comparability has not been reviewed for 45 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

vedolizumab

Clinical Remission 31.3% (n=383) vs 22.5% (n=386) Adalimumab @ 52wk300 mg IV
responder rate · % of participants
Maintenance
NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
56.1% (n=41) vs 31% (n=42) placebo @ 60wk300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
46.2% (n=106) vs 14.3% (n=56) placebo @ 52wk108 mg SC
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
41.8% (n=122) vs 15.9% (n=126) placebo @ 52wkQ8W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
44.8% (n=125) vs 15.9% (n=126) placebo @ 52wkQ4W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Endoscopic Improvement 36.6% (n=164) vs 30.5% (n=82) placebo @ 10wk300 mg
responder rate · % of participants
Induction
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
40.9% (n=225) vs 24.8% (n=149) placebo @ 6wk
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Durable Clinical 65.9% (n=41) vs 35.7% (n=42) placebo @ 60wk300 mg
responder rate · % of participants
Maintenance
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 3 more results
64.2% (n=106) vs 28.6% (n=56) placebo @ 52wk108 mg SC
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
56.6% (n=122) vs 23.8% (n=126) placeboQ8W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
52% (n=125) vs 23.8% (n=126) placeboQ4W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Endoscopic Improvement 39.7% (n=383) vs 27.7% (n=386) Adalimumab @ 52wk300 mg IV
responder rate · % of participants
Maintenance
NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
63.4% (n=41) vs 33.3% (n=42) placebo @ 60wk300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56.6% (n=106) vs 21.4% (n=56) placebo @ 52wk108 mg SC
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
51.6% (n=122) vs 19.8% (n=126) placebo @ 52wkQ8W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56% (n=125) vs 19.8% (n=126) placebo @ 52wkQ4W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Durable Clinical Remission 15.1% (n=106) vs 5.4% (n=56) placebo @ 52wk108 mg SC
responder rate · % of participants
Maintenance
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
show 2 more results
20.5% (n=122) vs 8.7% (n=126) placeboQ8W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
24% (n=125) vs 8.7% (n=126) placeboQ4W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Corticosteroid-free Clinical Remission 12.6% (n=111) vs 21.8% (n=119) Adalimumab @ 52wk300 mg IV
responder rate · % of participants
Maintenance
NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
46.2% (n=13) vs 20% (n=15) placebo @ 60wk300 mg
NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
28.9% (n=45) vs 8.3% (n=24) placebo @ 52wk108 mg SC
NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3
31.4% (n=70) vs 13.9% (n=72) placebo @ 52wkQ8W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.2% (n=73) vs 13.9% (n=72) placebo @ 52wkQ4W
NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Clinical Remission 31.9% (n=91) @ 14wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 36 more results
23.1% (n=91) @ 2wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
48.4% (n=91) @ 6wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
59.3% (n=91) @ 10wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
65.9% (n=91) @ 14wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
58.2% (n=91) @ 22wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
61.5% (n=91) @ 30wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
60.4% (n=91) @ 38wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
58.2% (n=91) @ 46wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
53.8% (n=91) @ 54wk300 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
39.2% (n=102) @ 14wk300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
43.1% (n=102) @ 30wk300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
52% (n=102) @ 46wk300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
44.4% (n=27) @ 14wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
29.6% (n=27) @ 2wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
59.3% (n=27) @ 6wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
55.6% (n=27) @ 10wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
77.8% (n=27) @ 14wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
59.3% (n=27) @ 22wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
70.4% (n=27) @ 30wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
70.4% (n=27) @ 38wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
74.1% (n=27) @ 46wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
66.7% (n=27) @ 54wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=3) @ 14wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=3) @ 2wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
66.7% (n=3) @ 6wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
66.7% (n=3) @ 10wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
66.7% (n=3) @ 14wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=3) @ 22wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0% (n=3) @ 30wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=3) @ 38wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=3) @ 46wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=3) @ 54wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
51.1% (n=47) @ 54wkLow Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
43.5% (n=46) @ 54wkHigh Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
53.2% (n=47) @ 54wkLow Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
43.5% (n=46) @ 54wkHigh Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Sustained Clinical Remission 29.8% (n=47) @ 54wkLow Dose
responder rate · % of participants
No placebo or comparator arm
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
28.3% (n=46) @ 54wkHigh Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Sustained Endoscopic Remission 36.2% (n=47) @ 54wkLow Dose
responder rate · % of participants
No placebo or comparator arm
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
30.4% (n=46) @ 54wkHigh Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Endoscopic 49.5% (n=91) @ 14wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 5 more results
21.6% (n=102) @ 46wk300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
48.1% (n=27) @ 14wk200 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
66.7% (n=3) @ 14wk150 mg
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
59.6% (n=47) @ 54wkLow Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
47.8% (n=46) @ 54wkHigh Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Corticosteroid-free Clinical Remission 56.5% (n=23) @ 54wkLow Dose
responder rate · % of participants
No placebo or comparator arm
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
27.8% (n=18) @ 54wkHigh Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Sustained Clinical 50% (n=2) @ 32wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT03196427 · Phase 2 · registry result, not featured evidence
show 5 more results
75% (n=8) @ 32wk200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
100% (n=2) @ 32wk150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
50% (n=4) @ 32wk100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
66% (n=47) @ 54wkLow Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
63% (n=46) @ 54wkHigh Dose
NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

+ 18 further endpoints in the CSV export.

Zotemtegrast

RHI -6.4 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Mayo Clinic -2.3 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2

Crohn's Disease

Shared mechanism: α4β7 integrin · full Crohn's Disease pipeline

vedolizumab · Entyvio

Marketed by Takeda Pharmaceutical Company

Approved in Crohn's Diseasemonoclonal antibody (humanized IgG1)
Partial signal

NCT00783692 · Phase 3 · completed

Design is strong (randomized, triple-blind, placebo-controlled, large adequately powered N=1115, hard clinical endpoint of CDAI-based remission), but per the mixed/partially-met test in the moderate definition, one of three co-primary endpoints (induction enhanced clinical response) missed significance while the others met it, so the overall primary endpoint result is discordant/mixed rather than a clean 'met' -- good design cannot upgrade a mixed result to strong.

Next expected readout: May 2027 · NCT06581328 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Clinical Remission at Week 52: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC) (met)

Result source: NCT02611817

Zotemtegrast

Developed by Eli Lilly

Phase 2 in Crohn's DiseaseSmall molecule (oral α4β7 integrin inhibitor)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2028 · NCT06226883 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointvedolizumabZotemtegrast
Clinical remission (induction)14.5% vs 6.8%+7.7 vs placebowk 6 · n 220NCT00783692
6 other results
  • 15.2% vs 12.1% wk 6 · n 158 · Phase 3 · primary NCT01224171
  • 9% vs 11.4% 300 mg · wk 10 · n 144 · Phase 3 · secondary NCT03234907
  • 17.7% vs 10.3% 300 mg · wk 10 · n 79 · Phase 3 · secondary NCT02038920
  • 26.6% vs 12.1% wk 10 · n 158 · Phase 3 · secondary NCT01224171
  • 28.7% vs 13% wk 10 · n 209 · Phase 3 · secondary NCT01224171
  • 19.1% vs 12.1% wk 6 · n 209 · Phase 3 · secondary NCT01224171
—Not reported
Endoscopic response (induction)—Trial running · NCT04779320—Not reported
Clinical remission (maintenance)48% vs 34.3%+13.7 vs placebo108 mg SC · wk 52 · n 275NCT02611817
4 other results
  • 39% vs 21.6% Q8W · wk 52 · n 154 · Phase 3 · primary NCT00783692
  • 36.4% vs 21.6% Q4W · wk 52 · n 154 · Phase 3 · primary NCT00783692
  • 41.7% vs 16.7% 300 mg · wk 60 · n 12 · Phase 3 · primary NCT02038920
  • 48.6% vs 42.9% 108 mg SC · wk 52 · n 107 · Phase 3 · secondary NCT02611817
—Not reported
Endoscopic response (maintenance)—Trial running · NCT04779320—Not reported

Clinical remission (induction)

vedolizumab
14.5% vs 6.8%+7.7 vs placebowk 6 · n 220NCT00783692
6 other results
  • 15.2% vs 12.1% wk 6 · n 158 · Phase 3 · primary NCT01224171
  • 9% vs 11.4% 300 mg · wk 10 · n 144 · Phase 3 · secondary NCT03234907
  • 17.7% vs 10.3% 300 mg · wk 10 · n 79 · Phase 3 · secondary NCT02038920
  • 26.6% vs 12.1% wk 10 · n 158 · Phase 3 · secondary NCT01224171
  • 28.7% vs 13% wk 10 · n 209 · Phase 3 · secondary NCT01224171
  • 19.1% vs 12.1% wk 6 · n 209 · Phase 3 · secondary NCT01224171
Zotemtegrast
—Not reported

Endoscopic response (induction)

vedolizumab
—Trial running · NCT04779320
Zotemtegrast
—Not reported

Clinical remission (maintenance)

vedolizumab
48% vs 34.3%+13.7 vs placebo108 mg SC · wk 52 · n 275NCT02611817
4 other results
  • 39% vs 21.6% Q8W · wk 52 · n 154 · Phase 3 · primary NCT00783692
  • 36.4% vs 21.6% Q4W · wk 52 · n 154 · Phase 3 · primary NCT00783692
  • 41.7% vs 16.7% 300 mg · wk 60 · n 12 · Phase 3 · primary NCT02038920
  • 48.6% vs 42.9% 108 mg SC · wk 52 · n 107 · Phase 3 · secondary NCT02611817
Zotemtegrast
—Not reported

Endoscopic response (maintenance)

vedolizumab
—Trial running · NCT04779320
Zotemtegrast
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zotemtegrast: no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. vedolizumab: 4 of 4 rows · Zotemtegrast: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricvedolizumab
Dropout rate
—VDZ/PBOa
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 58 more results
—VDZ/VDZ
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
6.2%
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—108 mg SC
NCT02611817 · Phase 3 · combination · Crohn's Disease · phase 3
22.8%300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
64.6%108 mg
NCT02620046 · Phase 3
56.6%108 mg
NCT02620046 · Phase 3
—Q2W
NCT02620046 · Phase 3
—QW
NCT02620046 · Phase 3
—Dose escalation from Q2W to QW
NCT02620046 · Phase 3
—Q2W
NCT02620046 · Phase 3
—QW
NCT02620046 · Phase 3
—Dose escalation from Q2W to QW
NCT02620046 · Phase 3
4.2%300 mg
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
—300 mg Q4W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
—300 mg Q4W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
—300 mg Q8W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
7.6%300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT00790933 · Phase 3 · monotherapy
54.2%300 mg
NCT03142321 · Phase 4 · registry result, not featured evidence
—300 mg every 4 weeks
NCT03142321 · Phase 4 · registry result, not featured evidence
—300 mg every 8 weeks
NCT03142321 · Phase 4 · registry result, not featured evidence
27.1%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
25.5%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
—300 mg (IV)
NCT02764762 · Phase 4 · registry result, not featured evidence
70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
9.1%300 mg
NCT02559713 · Phase 4 · registry result, not featured evidence
70%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
71.4%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
75%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
40%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
28.6%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
60%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
71.4%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
55.6%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
16.7%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
41.7%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg to 300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
25%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
15.4%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg to 200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
18.2%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
30%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
30%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
22.2%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
97.1%6 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
62.2%2 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03329209 · Phase 1 · registry result, not featured evidence
1.6%750 mg
NCT01981616 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—VDZ/PBOa
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 58 more results
—VDZ/VDZ
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1.9%
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—108 mg SC
NCT02611817 · Phase 3 · combination · Crohn's Disease · phase 3
2%300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
9.2%108 mg
NCT02620046 · Phase 3
7.6%108 mg
NCT02620046 · Phase 3
—Q2W
NCT02620046 · Phase 3
—QW
NCT02620046 · Phase 3
—Dose escalation from Q2W to QW
NCT02620046 · Phase 3
—Q2W
NCT02620046 · Phase 3
—QW
NCT02620046 · Phase 3
—Dose escalation from Q2W to QW
NCT02620046 · Phase 3
—300 mg
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
—300 mg Q4W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
—300 mg Q4W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
—300 mg Q8W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
3.8%300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg
NCT00790933 · Phase 3 · monotherapy
—300 mg
NCT03142321 · Phase 4 · registry result, not featured evidence
—300 mg every 4 weeks
NCT03142321 · Phase 4 · registry result, not featured evidence
—300 mg every 8 weeks
NCT03142321 · Phase 4 · registry result, not featured evidence
27.1%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
25.5%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
—300 mg (IV)
NCT02764762 · Phase 4 · registry result, not featured evidence
16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
9.1%300 mg
NCT02559713 · Phase 4 · registry result, not featured evidence
20%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
42.9%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
30%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
40%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
42.9%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
33.3%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
16.7%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
33.3%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg to 300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
16.7%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
7.7%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg to 200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
18.2%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
20%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
10%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
11.1%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
20%6 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
0%2 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03329209 · Phase 1 · registry result, not featured evidence
0%750 mg
NCT01981616 · Phase 1 · registry result, not featured evidence
Serious AEs
15%VDZ/PBOa
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 58 more results
24.4%VDZ/VDZ
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
6.2%
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
8.4%108 mg SC
NCT02611817 · Phase 3 · combination · Crohn's Disease · phase 3
—300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
11.9%300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
10.7%300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—108 mg
NCT02620046 · Phase 3
—108 mg
NCT02620046 · Phase 3
23%Q2W
NCT02620046 · Phase 3
29.9%QW
NCT02620046 · Phase 3
30.4%Dose escalation from Q2W to QW
NCT02620046 · Phase 3
17.8%Q2W
NCT02620046 · Phase 3
20%QW
NCT02620046 · Phase 3
36.9%Dose escalation from Q2W to QW
NCT02620046 · Phase 3
8.3%300 mg
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
26.3%300 mg Q4W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
28.4%300 mg Q4W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
30.4%300 mg Q8W
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
10.1%300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
16.7%300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
52.2%300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
36.8%300 mg
NCT00790933 · Phase 3 · monotherapy
—300 mg
NCT03142321 · Phase 4 · registry result, not featured evidence
0%300 mg every 4 weeks
NCT03142321 · Phase 4 · registry result, not featured evidence
0%300 mg every 8 weeks
NCT03142321 · Phase 4 · registry result, not featured evidence
4.2%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
5.9%300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
2.2%300 mg (IV)
NCT02764762 · Phase 4 · registry result, not featured evidence
10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
9.1%300 mg
NCT02559713 · Phase 4 · registry result, not featured evidence
40%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
16.7%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
42.9%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
33.3%300 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
50%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
50%150 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
33.3%100 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
80%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
16.7%200 mg
NCT03196427 · Phase 2 · registry result, not featured evidence
33.3%300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
11.1%150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
16.7%150 mg to 300 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
23.5%100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
50%100 mg to 200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
31.6%200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03138655 · Phase 2 · registry result, not featured evidence
20%6 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
8.1%2 mg/kg
NCT00619489 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03329209 · Phase 1 · registry result, not featured evidence
0%750 mg
NCT01981616 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
headache 18.3% (placebo 12.8%)
crohn's disease 15% (placebo 18.9%)
pyrexia 14.4% (placebo 11.5%)
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 44 more results
arthralgia 13.5% (placebo 12.8%)
pyrexia 12.5% (placebo 11.5%)
nasopharyngitis 12.3% (placebo 6.8%)
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
nausea 5.7% (placebo 2.4%)
headache 5.3% (placebo 7.2%)
pyrexia 3.3% (placebo 6.3%)
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
108 mg SC
crohn's disease 13.1% (placebo 17.2%)
nasopharyngitis 9.1% (placebo 4.5%)
abdominal pain 7.6% (placebo 8.2%)
NCT02611817 · Phase 3 · combination · Crohn's Disease · phase 3
300 mg
crohn's disease 11.9%
viral upper respiratory tract infection 5.9%
abdominal pain 5%
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg
crohn's disease 8.9%
abdominal pain 5.4%
viral upper respiratory tract infection 5.4%
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Q2W
upper respiratory tract infection 15.9%
arthralgia 14.2%
abdominal pain 13.8%
NCT02620046 · Phase 3
QW
crohn's disease 25.6%
abdominal pain 17.1%
nasopharyngitis 13.7%
NCT02620046 · Phase 3
Dose escalation from Q2W to QW
crohn's disease 52%
nasopharyngitis 19.6%
upper respiratory tract infection 17.6%
NCT02620046 · Phase 3
Q2W
upper respiratory tract infection 17.2%
covid-19 14.7%
nasopharyngitis 14.1%
NCT02620046 · Phase 3
QW
colitis ulcerative 23.3%
nasopharyngitis 18.3%
upper respiratory tract infection 10%
NCT02620046 · Phase 3
Dose escalation from Q2W to QW
colitis ulcerative 50.8%
nasopharyngitis 23.1%
anaemia 13.8%
NCT02620046 · Phase 3
300 mg
nasopharyngitis 9.7% (placebo 8.6%)
protein urine present 9% (placebo 7.1%)
pyrexia 9% (placebo 2.9%)
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
300 mg Q4W
blood urine present 13.2% (placebo 0%)
upper respiratory tract infection 10.5% (placebo 4.3%)
lymphocyte count decreased 7.9% (placebo 10%)
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
300 mg Q4W
upper respiratory tract infection 13.6% (placebo 4.3%)
pyrexia 12.5% (placebo 2.9%)
anaemia 11.4% (placebo 8.6%)
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
300 mg Q8W
anaemia 13% (placebo 8.6%)
pyrexia 13% (placebo 2.9%)
upper respiratory tract infection 10.9% (placebo 4.3%)
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
300 mg
nasopharyngitis 13.9% (placebo 14.1%)
enteritis infectious 5.1% (placebo 0%)
hypoaesthesia 5.1% (placebo 0%)
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg
nasopharyngitis 33.3% (placebo 14.1%)
allergy to metals 8.3% (placebo 0%)
anal abscess 8.3% (placebo 0%)
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg
nasopharyngitis 41% (placebo 14.1%)
crohn's disease 20.1% (placebo 6.4%)
pyrexia 14.2% (placebo 0%)
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg
nasopharyngitis 26.5%
arthralgia 21.5%
headache 20.2%
NCT00790933 · Phase 3 · monotherapy
300 mg
anaemia 12.5%
pyrexia 12.5%
headache 8.3%
NCT04804540 · Phase 4 · registry result, not featured evidence
300 mg
anaemia 7.8%
colitis ulcerative 6.9%
pyrexia 6.9%
NCT04804540 · Phase 4 · registry result, not featured evidence
300 mg (IV)
crohn's disease 44.4%
rash 11.1%
abdominal pain 8.9%
NCT02764762 · Phase 4 · registry result, not featured evidence
300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
arthralgia 18.2%
crohn's disease 16.4%
nasopharyngitis 10.9%
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
300 mg
crohn's disease 9.1%
gastrointestinal motility disorder 9.1%
paronychia 9.1%
NCT02559713 · Phase 4 · registry result, not featured evidence
300 mg
abdominal pain 30%
crohn's disease 30%
anaemia 20%
NCT03196427 · Phase 2 · registry result, not featured evidence
300 mg
crohn's disease 66.7%
diarrhoea 33.3%
oropharyngeal pain 33.3%
NCT03196427 · Phase 2 · registry result, not featured evidence
300 mg
arthralgia 28.6%
colitis ulcerative 28.6%
headache 28.6%
NCT03196427 · Phase 2 · registry result, not featured evidence
300 mg
colitis ulcerative 50%
abdominal pain 33.3%
diarrhoea 33.3%
NCT03196427 · Phase 2 · registry result, not featured evidence
150 mg
dehydration 50%
ear infection 50%
haemoglobin decreased 50%
NCT03196427 · Phase 2 · registry result, not featured evidence
150 mg
abdominal pain 50%
arthralgia 50%
asthma 50%
NCT03196427 · Phase 2 · registry result, not featured evidence
100 mg
anaemia 20%
asthma 20%
bronchitis 20%
NCT03196427 · Phase 2 · registry result, not featured evidence
100 mg
abdominal pain upper 33.3%
anaemia 33.3%
anaemia of chronic disease 33.3%
NCT03196427 · Phase 2 · registry result, not featured evidence
200 mg
crohn's disease 40%
upper respiratory tract infection 40%
abdominal pain 20%
NCT03196427 · Phase 2 · registry result, not featured evidence
200 mg
pyrexia 66.7%
arthralgia 50%
colitis ulcerative 50%
NCT03196427 · Phase 2 · registry result, not featured evidence
300 mg
headache 12.5%
pharyngitis 12.5%
pyrexia 12.5%
NCT03138655 · Phase 2 · registry result, not featured evidence
150 mg
ear infection 16.7%
bronchitis 11.1%
headache 11.1%
NCT03138655 · Phase 2 · registry result, not featured evidence
150 mg to 300 mg
cough 33.3%
dizziness 33.3%
headache 33.3%
NCT03138655 · Phase 2 · registry result, not featured evidence
100 mg
abdominal pain 29.4%
arthralgia 11.8%
crohn's disease 11.8%
NCT03138655 · Phase 2 · registry result, not featured evidence
100 mg to 200 mg
diarrhoea 50%
vomiting 50%
abdominal distension 25%
NCT03138655 · Phase 2 · registry result, not featured evidence
200 mg
abdominal pain 15.8%
anaemia 15.8%
oropharyngeal pain 15.8%
NCT03138655 · Phase 2 · registry result, not featured evidence
6 mg/kg
headache 20%
nasopharyngitis 20%
cough 14.3%
NCT00619489 · Phase 2 · registry result, not featured evidence
2 mg/kg
nasopharyngitis 13.5%
carpal tunnel syndrome 5.4%
headache 5.4%
NCT00619489 · Phase 2 · registry result, not featured evidence
300 mg
upper respiratory tract infection 25%
leukocyturia 12.5%
blood creatine phosphokinase increased 6.3%
NCT03329209 · Phase 1 · registry result, not featured evidence
750 mg
headache 18.8% (placebo 12.7%)
viral upper respiratory tract infection 12.5% (placebo 12.7%)
nausea 6.3% (placebo 0%)
NCT01981616 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 45 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

vedolizumab

Clinical Remission 9% (n=144) vs 11.4% (n=70) placebo @ 10wk300 mg
responder rate · % of participants
Induction
NCT03234907 · Phase 3 · Crohn's Disease · phase 3
show 6 more results
17.7% (n=79) vs 10.3% (n=78) placebo @ 10wk300 mg
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
14.5% (n=220) vs 6.8% (n=148) placebo @ 6wk
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
15.2% (n=158) vs 12.1% (n=157) placebo @ 6wk
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
19.1% (n=209) vs 12.1% (n=207) placebo @ 6wk
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
26.6% (n=158) vs 12.1% (n=157) placebo @ 10wk
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
28.7% (n=209) vs 13% (n=207) placebo @ 10wk
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Enhanced Clinical 31.4% (n=220) vs 25.7% (n=148) placebo @ 6wk
responder rate · % of participants
Induction
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
39.2% (n=158) vs 22.3% (n=157) placebo @ 6wk
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Remission 41.7% (n=12) vs 16.7% (n=12) placebo @ 60wk300 mg
responder rate · % of participants
Maintenance
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 4 more results
48% (n=275) vs 34.3% (n=134) placebo @ 52wk108 mg SC
NCT02611817 · Phase 3 · combination · Crohn's Disease · phase 3
48.6% (n=107) vs 42.9% (n=63) placebo @ 52wk108 mg SC
NCT02611817 · Phase 3 · combination · Crohn's Disease · phase 3
39% (n=154) vs 21.6% (n=153) placebo @ 52wkQ8W
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
36.4% (n=154) vs 21.6% (n=153) placebo @ 52wkQ4W
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Enhanced Clinical 52% (n=275) vs 44.8% (n=134) placebo @ 52wk108 mg SC
responder rate · % of participants
Maintenance
NCT02611817 · Phase 3 · combination · Crohn's Disease · phase 3
show 2 more results
43.5% (n=154) vs 30.1% (n=153) placebo @ 52wkQ8W
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
45.5% (n=154) vs 30.1% (n=153) placebo @ 52wkQ4W
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Corticosteroid-free Clinical Remission 40% (n=5) vs 0% (n=3) placebo @ 60wk300 mg
responder rate · % of participants
Maintenance
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 3 more results
45.3% (n=95) vs 18.2% (n=44) placebo @ 52wk108 mg SC
NCT02611817 · Phase 3 · combination · Crohn's Disease · phase 3
31.7% (n=82) vs 15.9% (n=82) placebo @ 52wkQ8W
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
28.8% (n=80) vs 15.9% (n=82) placebo @ 52wkQ4W
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Durable Clinical Remission 33.3% (n=12) vs 25% (n=12) placebo @ 60wk300 mg
responder rate · % of participants
Maintenance
NCT02038920 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 2 more results
21.4% (n=154) vs 14.4% (n=153) placeboQ8W
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
16.2% (n=154) vs 14.4% (n=153) placeboQ4W
NCT00783692 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Sustained Clinical Remission 12% (n=158) vs 8.3% (n=157) placebo
responder rate · % of participants
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
15.3% (n=209) vs 8.2% (n=207) placebo
NCT01224171 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Endoscopic Remission 11.9% (n=101) @ 26wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 3 more results
16.8% (n=101) @ 14wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
16.1% (n=56) @ 52wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
34.5% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
Complete Mucosal Healing 14.9% (n=101) @ 26wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
17.9% (n=56) @ 52wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Endoscopic 33.7% (n=101) @ 14wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 4 more results
24.8% (n=101) @ 26wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
51.8% (n=56) @ 52wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
12.5% (n=48) @ 46wk300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
56.4% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
CDAI 54.5% (n=101) @ 10wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 2 more results
60.4% (n=101) @ 26wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
58.9% (n=56) @ 52wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Remission 35.6% (n=101) @ 10wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 7 more results
41.6% (n=101) @ 26wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
50% (n=56) @ 52wk300 mg
NCT02425111 · Phase 3 · monotherapy · Crohn's Disease · phase 3
47.9% (n=48) @ 14wk300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
45.8% (n=48) @ 30wk300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
56.3% (n=48) @ 46wk300 mg
NCT04804540 · Phase 4 · registry result, not featured evidence
60% (n=55) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
54.5% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination

+ 34 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: vedolizumab's landscape · Zotemtegrast's landscape